🤯 Picked by our AI, this stock rallied more than Nvidia this month, yielding 94% since MarchSee the stock

Trevi Therapeutics appoints new VP for clinical development

EditorRachael Rajan
Published 02/04/2024, 13:24
TRVI
-

NEW HAVEN, Conn. - Trevi Therapeutics, Inc. (NASDAQ: NASDAQ:TRVI), a clinical-stage biopharmaceutical company, announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development.

Dr. Garin's role will focus on advancing the clinical development of Haduvio™, the company's investigational therapy for chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

Dr. Garin brings over 14 years of industry and academic research experience to Trevi Therapeutics. With a background in leading global clinical trials, her expertise is expected to be instrumental in progressing Haduvio through its current and future clinical trials. Before joining Trevi, Dr. Garin held a lead role in clinical development at Bellus Health, where she was responsible for a successful Phase 2b study and the development of a Phase 3 RCC program.

David Clark, Chief Medical Officer of Trevi Therapeutics, expressed his confidence in Dr. Garin's ability to contribute to the company's mission, highlighting her extensive knowledge and experience in managing clinical trials for chronic cough treatments.

Haduvio, an oral nalbuphine ER, is a dual kappa-opioid receptor agonist and mu-opioid receptor antagonist. It aims to provide a synergistic antitussive effect and address the significant impact of chronic cough on patients' quality of life. Currently, there are no approved therapies in the United States for chronic cough in IPF or RCC, and Haduvio's development could potentially meet this unmet medical need.

This announcement is based on a press release statement from Trevi Therapeutics.

InvestingPro Insights

As Trevi Therapeutics, Inc. (NASDAQ: TRVI) fortifies its clinical development team with the appointment of Dr. Margaret Garin, investors may be keen to understand the financial health and market performance of the company. Here are some insights based on real-time data from InvestingPro and curated InvestingPro Tips:

The company's market capitalization stands at a modest $231.71 million, reflecting its status as a clinical-stage biopharmaceutical company with significant growth potential. Despite challenges, such as weak gross profit margins and the anticipation of a drop in net income this year, Trevi Therapeutics holds more cash than debt on its balance sheet, a reassuring sign of financial stability for investors. Moreover, the company's liquid assets exceed its short-term obligations, providing some cushion for operational needs.

InvestingPro Data metrics reveal a Price to Earnings (P/E) Ratio of -11.55 and an adjusted P/E Ratio for the last twelve months as of Q4 2023 at -7.97, indicating that the company is not currently profitable. The negative EBITDA growth of -13.18% over the same period reflects operational challenges. However, investors have seen a strong return over the last month, three months, and six months, with the price total return reaching 158.46% over the past three months and 65.52% over the past six months. This suggests that the market may be responding positively to the company's long-term prospects and development milestones.

Among the InvestingPro Tips, it's notable that analysts do not anticipate the company will be profitable this year, and Trevi Therapeutics does not pay a dividend to shareholders. This could be a point of consideration for those focused on immediate income versus long-term capital gains. The strong return over the last year, with an 81.62% price total return, may appeal to growth-oriented investors.

To gain a deeper understanding of Trevi Therapeutics' financials and market performance, interested readers can explore additional insights with InvestingPro. There are 11 InvestingPro Tips available, which can be accessed by visiting https://www.investing.com/pro/TRVI. For those looking to subscribe, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.